The Top 5 Biosimilars Articles for the Week of June 1

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of June 1, 2020.

Number 5: Cancer drug prices are rising in the United States and Europe, but European regulators negotiate drug prices, and the results are seen in pricing trends, investigators said in a presentation for ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology.

Number 4: Abstracts presented at ASCO20 Virtual revealed important data on physician prescribing of biosimilars and cost savings in the oncology space.

Number 3: The rituximab biosimilar candidate ABP 798 met primary and secondary end points for safety, efficacy, and immunogenicity in a study presented at ASCO20 Virtual.

Number 2: In a settlement announced via a Securities and Exchange Commission filing, Alexion said it had settled with Amgen over eculizumab patent disputes, allowing Amgen to bring a competing biosimilar to market in 2025.

Number 1: A study presented at ASCO20 Virtual demonstrated the power of biosimilar pegfilgrastim to lower costs in the Oncology Care Model (OCM), where pegfilgrastim expense amounts to 5.3% of the total cost of cancer care.

To read all of these articles and more, visit centerforbiosimilars.com.